Emergent to resume J&J COVID-19 vaccine production at Baltimore plant
Reuters
Published Jul 28, 2021 11:41PM ET
Updated Jul 29, 2021 06:35PM ET
(Reuters) -Emergent BioSolutions said it will resume production of Johnson & Johnson (NYSE:JNJ)'s COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated.
The development was announced late on Wednesday. Last week, J&J slashed 2021 production target of its single-dose vaccine to between 500 million and 600 million doses from its original goal to produce a billion shots.
The resumption follows additional reviews and collaboration with the FDA and manufacturing partners, Emergent Chief Executive Officer Robert Kramer said.
The FDA has so far approved five batches from the Emergent facility since production there was paused, and J&J is working to clear additional doses for use, the drugmaker said last week.
Emergent expects the FDA to approve additional batches of J&J shots, Kramer said during Emergent's Thursday investor call.
U.S. health regulators in April halted operations at the Baltimore plant following a discovery that ingredients from AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine, also being produced there at that time, contaminated a batch of J&J's vaccines.
That month, the U.S. government asked Emergent to stop making AstraZeneca shots after it discovered the cross contamination.
"We continue to work collaboratively with AstraZeneca to complete all documents related to their drug substance so they and the U.S. government can make decisions regarding the disposition of this material," Kramer said during the call.
An FDA inspection also turned up a long list of sanitary problems and bad manufacturing practices.
J&J's vaccine, considered more convenient for use, storing and shipping to remote areas, has seen a relatively slow uptake in Europe and the United States due to safety concerns and the production issues.
"We will continue to work toward securing Emergency Use Authorization in the United States for drug substance manufactured at Emergent Bayview as quickly as possible," J&J said in an email.
The FDA did not immediately respond to a Reuters request for comment.
The Wall Street Journal, which first reported the news, cited a letter from the FDA saying the agency had no objections with the plant resuming manufacturing. (https://on.wsj.com/3iXSAfg)
Get The News You Want
The facility could make as many as 120 million doses a month at full capacity, but the finished doses might not be available until this fall, the Journal reported.
Emergent expects to launch in the near future a late stage study for a COVID-19 therapeutic it is developing in partnership with the U.S. government, executives said on the investor call.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.